Male Breast Cancer in Australia

Lomma, Chris; Chan, Arlene; Chih, HuiJun; Reid, Christopher M.; Peter, Willsher

doi:10.1111/ajco.13299

Cited by 9 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Information on clinical characteristics, treatment history, and response to abemaciclib-containing treatment for six patients is described here. Similar to other RWE analyses of CDK 4&6I in men [13,14,19], the number of male patients included in this analysis is small; however, on a percentage basis (1.8%), this aligns with the US and global prevalence of MBC in males [1,2].…”

Section: Discussionsupporting

confidence: 67%

“…Male breast cancer constitutes 0.5-1% of all breast cancer cases globally [1,2]. More than 90% of male patients have the hormone receptor-positive (HR?…”

Section: Introductionmentioning

confidence: 99%

“…Male breast cancer constitutes 0.5–1% of all breast cancer cases globally [ 1 , 2 ]. More than 90% of male patients have the hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) subtype, and treatment recommendations for these patients are often extrapolated based on breast cancer treatment in women, despite well-recognized differences in the clinicopathological features between genders [ 2 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

et al. 2023

View full text Add to dashboard Cite

Introduction: Breast cancer in males constitutes approximately 1% of all breast cancer cases globally. Despite extensive treatment experience with abemaciclib in women with metastatic breast cancer (MBC), real-world evidence in male MBC is lacking. Methods: This analysis was a part of a broader, retrospective study that analyzed electronic medical records and charts of 448 men and women with hormone receptor-positive (HR?), human epidermal growth factor receptor 2-negative (HER2-) MBC who initiated an abemaciclib-containing regimen from January 2017 through September 2019. Data were collected from the Florida Cancer Specialists & Research Institute and the Electronic Medical Office Logistics Health Oncology Warehouse Language TM databases and summarized descriptively. Real-world best response was described: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Results: Data for six male patients with MBC who were treated with abemaciclib in combination with an aromatase inhibitor (AI) or fulvestrant are presented. Four patients were aged C 75 years, and four patients had C 3 metastatic sites, including visceral involvement. Abemaciclib was initiated in/after third-line (C 3L) in four patients, and patients had history of treatment with AI (n = 4), chemotherapy (n = 3), and/or prior cyclin-dependent kinase 4 and 6 inhibitors (n = 2) in the metastatic setting. Abemaciclib ? fulvestrant was the most common abemaciclib-containing regimen (n = 4). Best response was documented in four patients: 1 each with CR, PR, SD, and PD. Conclusion: Prevalence of male MBC in this dataset was consistent with expected prevalence in the broader population. Most male patients received an abemaciclib-containing regimen in C 3L, with anti-cancer activity observed despite heavy metastatic burden and prior treatments in a metastatic setting.

show abstract

Section: Discussionsupporting

confidence: 67%

“…Male breast cancer constitutes 0.5-1% of all breast cancer cases globally [1,2]. More than 90% of male patients have the hormone receptor-positive (HR?…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Male breast cancer is a rare malignancy that accounts for less than 1% of all breast cancers [ 70 ] in some populations. It accounts for 0.48% of cases in the South Korean populations [ 71 ], 0.6% in the Australian population [ 72 ], 0.9% in the American population [ 73 ], and 0.55% in the Danish population [ 74 ]. Of course, there are some populations with higher rates of breast cancer in men.…”

Section: Discussionmentioning

confidence: 99%

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients

Zhang

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Objective To investigate the prevalence and spectrum of BRCA1 and BRCA2 mutations in Chinese Hakka patients with breast and ovarian cancer. Methods A total of 1,664 breast or ovarian cancer patients were enrolled for genetic testing at our hospital. Germline mutations of the BRCA gene were analysed by next-generation sequencing, including the coding regions and exon intron boundary regions. Results The 1,664 patients included 1,415 (85.04%) breast cancer patients and 245 (14.72%) ovarian cancer patients, while four (0.24%) patients had both the breast and ovarian cancers. A total of 151 variants, including 71 BRCA1 variants and 80 BRCA2 variants, were detected in the 234 (14.06%) patients. The 151 variants included 58 pathogenic variants, 8 likely pathogenic variants, and 85 variants of unknown significance (VUS). A total of 56.25% (18/32) and 65.38% (17/26) of pathogenic variants (likely pathogenic variants are not included) were distributed in exon 14 of BRCA1 and exon 11 of BRCA2, respectively. The most common pathogenic variants among this Hakka population are c.2635G > T (p.Glu879*) (n = 7) in the BRCA1 gene and c.5164_5165del (p.Ser1722Tyrfs*4) (n = 7) in the BRCA2 gene among the Hakka population. A hotspot mutation in the Chinese population, the BRCA1 c.5470_5477del variant was not found in this Hakka population. The prevalence and spectrum of variants in the BRCA genes in the Hakka patients are different from that in other ethnic groups. Conclusions The most common pathogenic variant in this population is c.2635G > T in the BRCA1 gene, and c.5164_5165delAG in the BRCA2 gene in this population. The prevalence and spectrum of variants in the BRCA1 and BRCA2 genes in the Hakka patients from southern China are different from those in other ethnic groups.

show abstract

“…It also caused 685,000 deaths, which accounted for 6.9% of deaths caused by all cancers. Men can also have breast cancer, although it is more than 100 times less common than in women [ 20 ]. For this reason, this subsection will only discuss the role of CXCL1 in female breast cancer.…”

Section: Breast Cancermentioning

confidence: 99%

Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer

Korbecki

Bosiacki

Barczak

et al. 2023

IJMS

View full text Add to dashboard Cite

C-X-C motif chemokine ligand 1 (CXCL1) is a member of the CXC chemokine subfamily and a ligand for CXCR2. Its main function in the immune system is the chemoattraction of neutrophils. However, there is a lack of comprehensive reviews summarizing the significance of CXCL1 in cancer processes. To fill this gap, this work describes the clinical significance and participation of CXCL1 in cancer processes in the most important reproductive cancers: breast cancer, cervical cancer, endometrial cancer, ovarian cancer, and prostate cancer. The focus is on both clinical aspects and the significance of CXCL1 in molecular cancer processes. We describe the association of CXCL1 with clinical features of tumors, including prognosis, ER, PR and HER2 status, and TNM stage. We present the molecular contribution of CXCL1 to chemoresistance and radioresistance in selected tumors and its influence on the proliferation, migration, and invasion of tumor cells. Additionally, we present the impact of CXCL1 on the microenvironment of reproductive cancers, including its effect on angiogenesis, recruitment, and function of cancer-associated cells (macrophages, neutrophils, MDSC, and Treg). The article concludes by summarizing the significance of introducing drugs targeting CXCL1. This paper also discusses the significance of ACKR1/DARC in reproductive cancers.

show abstract

Male Breast Cancer in Australia

Cited by 9 publications

References 20 publications

Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients

Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer

Contact Info

Product

Resources

About